Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicentre, Open Label, Observational 24-week Study to Evaluate Safety of Initiating Insulin Therapy With Levemir® (Insulin Detemir) Once-daily in Oral Antidiabetic Drug-treated Patients With Type 2 Diabetes

NCT00825643 is registered in ClinicalTrials.gov with Novo Nordisk A/S as lead sponsor.

NCT NCT00825643
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00825643 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicentre, Open Label, Observational 24-week Study to Evaluate Safety of Initiating Insulin Therapy With Levemir® (Insulin Detemir) Once-daily in Oral Antidiabetic Drug-treated Patients With Type 2 Diabetes
Lead sponsor
Novo Nordisk A/S
Phase
Observational
Overall status
Completed
Start date
April 30, 2008
Completion date
March 31, 2011
Enrollment
18,481 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

diabetes, diabetes mellitus, type 2